AUA 2018: Refining Immunotherapy Combinations and Sequencing in Bladder CancerUroTodayHe noted that immunotherapy is an exciting and well-tolerated agent in the treatment of urothelial carcinoma, however, only 15-20% of patients derive significant bene… Continue reading
AUA 2018: Immunotherapy in Renal Cell Carcinoma: Current Standing and Future DirectionsUroTodayDr. Campbell began by exploring the historical and present use of high dose Interleukin-2 (IL-2), as the initial form of immunotherapy used for renal cell ca… Continue reading
AUA 2018: Immunotherapy in Renal Cell Carcinoma: Current Standing and Future DirectionsUroTodayDr. Campbell began by exploring the historical and present use of high dose Interleukin-2 (IL-2), as the initial form of immunotherapy used for renal cell ca… Continue reading
AUA 2018: Overview of Immunotherapy in GU CancersUroTodayCurrently, in prostate cancer, only one approved immunotherapy exists, Sipuleucel-T, for patients with minimally symptomatic or asymptomatic metastatic castrate resistant prostate cancer. However… Continue reading
AUA 2018: Overview of Immunotherapy in GU CancersUroTodayCurrently, in prostate cancer, only one approved immunotherapy exists, Sipuleucel-T, for patients with minimally symptomatic or asymptomatic metastatic castrate resistant prostate cancer. However… Continue reading
AUA 2018: Overview of Immunotherapy in GU CancersUroTodayCurrently, in prostate cancer, only one approved immunotherapy exists, Sipuleucel-T, for patients with minimally symptomatic or asymptomatic metastatic castrate resistant prostate cancer. However… Continue reading
|
Stem cell transplant, Rituxan hold ‘tremendous promise’ for ILD with systemic sclerosis
Healio DESTIN, Fla. — Stem cell transplantation, rituximab and tocilizumab show considerable promise as treatments for interstitial lung disease in systemic sclerosis among select patients, according to findings presented at the 2018 Congress of Clinical … |